• In May 2026, POET Technologies Inc. closed a US$400.00 million registered direct follow-on offering of 19,047,620 common shares and the same number of warrants, shortly after announcing a multi-year joint development and supply agreement with Lumilens that includes an initial US$50 million order and potential purchases up to US$500 million.
• By tying a nine-year warrant package to Lumilens’ spending milestones, POET has directly aligned equity incentives with the ramp-up of its AI photonics revenue pipeline.
• Next, we’ll examine how this Lumilens-backed expansion plan and fresh US$400 million capital injection reshape POET Technologies’ investment narrative.

Uncover the next big thing with 27 elite penny stocks that balance risk and reward.

What Is POET Technologies' Investment Narrative?

To own POET Technologies today, you have to buy into a very specific story: a pre-profit photonics company trying to convert a string of AI-focused partnerships into meaningful revenue, while funding that ambition through heavy equity issuance. The Lumilens deal and the US$400.00 million direct offering both sit at the center of that story. On one hand, Lumilens’ initial US$50 million order and milestone-tied warrants give POET a clearer commercial path and help justify a roughly tenfold capacity build-out. On the other, the fresh capital comes with further dilution on top of a year where existing holders have already been heavily diluted. In the near term, the key catalysts now cluster around execution: hitting joint-development milestones, delivering sample timelines and proving that this much larger balance sheet can translate into a real AI photonics business before investor patience wears thin amid legal and tax overhangs.

However, there is one risk in particular here that current and prospective shareholders should not ignore. According our valuation report, there's an indication that POET Technologies' share price might be on the expensive side.

Exploring Other Perspectives

Eight fair value estimates from the Simply Wall St Community span roughly US$0.69 to US$21.10 per share, underscoring how divided private investors are on POET. Set against a business that is still loss making, heavily dilutive and reliant on future Lumilens and other AI orders, this spread reflects just how differently the same story can be interpreted.

Explore 8 other fair value estimates on POET Technologies - why the stock might be worth as much as 43% more than the current price!

Reach Your Own Conclusion

Don't just follow the ticker - dig into the data and build a conviction that's truly your own.

• A great starting point for your POET Technologies research is our analysis highlighting 1 key reward and 4 important warning signs that could impact your investment decision.
• Our free POET Technologies research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate POET Technologies' overall financial health at a glance.

Ready For A Different Approach?

The market won't wait. These fast-moving stocks are hot now. Grab the list before they run:

• AI is about to change healthcare. These 30 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Capitalize on the AI infrastructure supercycle with our selection of the 44 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
• Invest in the nuclear renaissance through our list of 88 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.